ABSTRACT
Introduction: There is no clear evidence in the literature that platelet-rich plasma (PRP) injections improve female sexual dysfunction (FSD) and female stress urinary incontinence (SUI). Objectives: A systematic review was performed to study the efficacy and safety of PRP injections in women with the above pathologies, as well as to explore the optimal dosing, frequency and area of injections, and duration of treatment. Methods: A systematic search on PubMed, Embase and the Cochrane Library database was performed, as well as sources of grey literature from the date of database or source creation to January 2023. After title/abstract and full-text screening, clinical studies on humans evaluating the efficacy of PRP in gynecological disorders using standardized tools were included. Risk of bias was undertaken with RoB-2 for randomized-controlled trials (RCT) and the Newcastle-Ottawa Scale (NOS) for observational studies. Results: Four prospective and one retrospective study explored FSD, while six prospective and one RCT evaluated female SUI. A total of 327 women with a mean age of 51 ± 12 years were included. For FSD, PRP significantly improved the Female Sexual Function Index (FSFI), the Vaginal Health Index (VHI) and the Female Sexual Distress score (FSDS). For SUI, PRP led to a significant improvement in the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) and the Urogenital Distress Inventory (UDI-6). The identified RCT reported a significantly higher mean score of ICIQ-SF (p < 0.05) and UDI-6 (p < 0.01) in the midurethral sling group compared to the PRP injections group. Regarding the risk of bias, the RCT was characterized by high risk, whereas the observational studies were of moderate risk. The protocol for PRP injections for FSD is the injection of 2 mL of PRP into the distal anterior vaginal wall once a month for 3 months. For female SUI, 5-6 mL of PRP should be injected into the periurethral area once a month for 3 months. Conclusions: Despite the promising initial results of PRP injections, the level of current evidence is low due to methodological issues in the available studies. It becomes clear that there is an emerging need for high-quality research examining PRP injections for the treatment of FSD and female SUI.
ABSTRACT
The performed clinical laboratory and instrumental research involved 93 pregnant women after IVF: 36 with progressive pregnancy and 57 women with missed abortion at term 6-8 weeks. The following parameters were evaluated: family history of thrombosis, menstrual function, gynecological and other diseases, duration of infertility treatment, pelvic organs sonography, hemostasis evaluation and thrombophilia genes investigation. The association of polymorphic allele 455 A of gene FGB with the risk of nondeveloping pregnancy after IVF was revealed. The genotype presence of allele 455 A of gene FGB increases the risk of miscarriage after IVF. The research has also revealed the association of polymorphic allele 4 G of gene PAI-1 in polymorphic locus 675:4 G/5 G with the risk of miscarriage. The received data on hemostatic system at an early term of pregnancy after IVF demonstrate enough stability and consistent thrombocytic and coagulative hemostasis of all examined women. Patients with progressive pregnancy have a considerably lower level of platelets than the patients with miscarriage. The average content of fibrinogen in women with progressive pregnancy is considerably higher than that in the patients in other groups. APTT is positively higher in patients of group A. The average content of SFMC in patients of group A was positively higher. The patients with non-developing pregnancy after IVF showed a considerably lower SFMC content.
